{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:47:59Z","timestamp":1794944879499,"version":"4.9.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jacc.2023.05.055","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T13:59:17Z","timestamp":1691416757000},"page":"648-660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":204,"title":["Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease"],"prefix":"10.1016","volume":"82","author":[{"given":"Kyle","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1249-4522","authenticated-orcid":false,"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2023.05.055_bib1","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2020.11.079","article-title":"New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B: JACC focus seminar","volume":"77","author":"Nurmohamed","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.05.055_bib2","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1093\/eurheartj\/ehab841","article-title":"The dawn of a new era of targeted lipid-lowering therapies","volume":"43","author":"Tokgozoglu","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.05.055_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.05.055_bib4","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomized trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2023.05.055_bib5","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.05.055_bib6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.05.055_bib7","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.05.055_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Statin therapy, LDL cholesterol, C-reactive protein, and coronary disease","volume":"352","author":"Nissen","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.05.055_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-Reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.05.055_bib10","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.05.055_bib11","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.05.055_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIRCULATIONAHA.106.628909","article-title":"Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial","volume":"114","author":"Morrow","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.05.055_bib13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.05.055_bib14","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.05.055_bib15","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.05.055_bib16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.05.055_bib17","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.05.055_bib18","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.05.055_bib19","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCRESAHA.117.312200","article-title":"CANTOS: a gigantic proof-of-concept trial","volume":"121","author":"Ibanez","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2023.05.055_bib20","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.05.055_bib21","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti\u2013interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2023.05.055_bib22","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.05.055_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00296-008-0710-9","article-title":"How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases?","volume":"29","author":"Beck","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jacc.2023.05.055_bib24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s11739-019-02035-1","article-title":"Update on the treatment of Behcet\u2019s syndrome","volume":"14","author":"Esatoglu","year":"2019","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jacc.2023.05.055_bib25","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","volume":"61","author":"O\u2019Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.05.055_bib26","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.05.055_bib27","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.V83.9.2451.2451","article-title":"P-Glycoprotein expression and function in circulating blood cells with normal volunteers","volume":"83","author":"Klimecki","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2023.05.055_bib28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/art.1780080438","article-title":"Colchicine inhibition of chemotaxis","volume":"8","author":"Caner","year":"1965","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jacc.2023.05.055_bib29","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1172\/JCI118147","article-title":"Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils","volume":"96","author":"Cronstein","year":"1995","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2023.05.055_bib30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0171-2985(96)80027-1","article-title":"Inhibition of LPS-induced tumor necrosis factor-alpha production by colchicine and other microtubule disrupting drugs","volume":"195","author":"Li","year":"1996","journal-title":"Immunobiology"},{"key":"10.1016\/j.jacc.2023.05.055_bib31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2023.05.055_bib32","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/ni.3457","article-title":"Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS","volume":"17","author":"Park","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jacc.2023.05.055_bib33","first-page":"531","article-title":"Colchicine antagonizes the activity of human smooth muscle cells cultivated from arteriosclerotic lesions after atherectomy","volume":"5","author":"Bauriedel","year":"1994","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.jacc.2023.05.055_bib34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s42255-021-00366-y","article-title":"Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation","volume":"3","author":"Weng","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.jacc.2023.05.055_bib35","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2006.10.039","article-title":"Effect of colchicine (0.5mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease","volume":"99","author":"Nidorf","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2023.05.055_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","article-title":"Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study","volume":"11","author":"Vaidya","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Img"},{"issue":"suppl 1","key":"10.1016\/j.jacc.2023.05.055_bib37","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/kex453","article-title":"Update on colchicine, 2017","volume":"57","author":"Slobodnick","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jacc.2023.05.055_bib38","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00296-021-04876-6","article-title":"The incidence and prevalence of cardiovascular diseases in gout: a systemic review and meta-analysis","volume":"41","author":"Cox","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jacc.2023.05.055_bib39","first-page":"1722","article-title":"Colchicine use and incident coronary artery disease in male patients with gout","volume":"36","author":"Shah","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2023.05.055_bib40","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.111533","article-title":"Colchicine use is associated with the decreased prevalence of myocardial infarction in patients with gout","volume":"39","author":"Crittenden","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jacc.2023.05.055_bib41","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.05.055_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2022.12.026","article-title":"Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial","volume":"372","author":"Opstal","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2023.05.055_bib43","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jacc.2021.06.037","article-title":"Colchicine in patients with chronic coronary disease in relation to prior acute coronary syndrome","volume":"78","author":"Opstal","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.05.055_bib44","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacc.2017.07.764","article-title":"Using absolute event rates to see what works in cardiovascular medicine","volume":"70","author":"Bittl","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.05.055_bib45","first-page":"1837","article-title":"Colchicine for prevention of atherothrombotic events in patients with coronary artery disease: review and practical approach for clinicians","volume":"37","author":"Marquis-Gravel","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2023.05.055_bib46","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40261-022-01209-8","article-title":"The effect of years-long exposure to low-dose colchicine on renal and liver function and blood creatinine kinase levels: safety insights from the Low-Dose Colchicine 2 (LoDoCo2) trial","volume":"42","author":"van Broekhoven","year":"2022","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jacc.2023.05.055_bib47","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.115.017611","article-title":"Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study","volume":"132","author":"Deftereos","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.05.055_bib48","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ahj.2019.06.003","article-title":"The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction","volume":"215","author":"Hennessy","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2023.05.055_bib49","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.05.055_bib50","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1093\/eurheartj\/ehab221","article-title":"Colchicine and the heart","volume":"42","author":"Imazio","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.05.055_bib51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12471-021-01605-3","article-title":"Targeting residual inflammatory risk in coronary disease: to catch a monkey by its tail","volume":"30","author":"Fiolet","year":"2022","journal-title":"Neth Heart J"},{"key":"10.1016\/j.jacc.2023.05.055_bib52","first-page":"776","article-title":"Colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Samuel","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2023.05.055_bib53","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/phar.2674","article-title":"A\u00a0systematic review of the drug-drug interaction between statins and colchicine: patient characteristics, etiologies, and clinical management strategies","volume":"42","author":"Schwier","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacc.2023.05.055_bib54","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.05.055_bib56","first-page":"99","volume":"92","author":"Ponte-Negretti","year":"2022","journal-title":"Arch Cardiol Mex"},{"key":"10.1016\/j.jacc.2023.05.055_bib57","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","article-title":"Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease","volume":"135","author":"Robinson","year":"2022","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2023.05.055_bib58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.121.056171","article-title":"Colchicine in cardiovascular disease: in depth review","volume":"145","author":"Deftereos","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.05.055_bib59","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/431592","article-title":"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study","volume":"41","author":"Hung","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jacc.2023.05.055_bib60","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0049-0172(91)90019-V","article-title":"Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years","volume":"20","author":"Ben-Chetrit","year":"1991","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.jacc.2023.05.055_bib61","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2459\/JCM.0000000000001157","article-title":"Adverse events of colchicine for cardiovascular diseases: a comprehensive meta-analysis of 14,188 patients from 21 randomized controlled trials","volume":"22","author":"Andreis","year":"2021","journal-title":"J\u00a0Cardiovasc Med (Hagerstown)"},{"issue":"1","key":"10.1016\/j.jacc.2023.05.055_bib62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13075-020-2120-7","article-title":"Adverse events during oral colchicine use: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Stewart","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jacc.2023.05.055_bib63","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/ehjqcco\/qcaa045","article-title":"Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT","volume":"7","author":"Samuel","year":"2021","journal-title":"). Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jacc.2023.05.055_bib64","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.119.045256","article-title":"From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents?","volume":"141","author":"Ridker","year":"2020","journal-title":"Circulation"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723059600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723059600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:27:04Z","timestamp":1770773224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109723059600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0735109723059600"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2023.05.055","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2023.05.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}